Curanex Pharmaceuticals Files 8-K
Ticker: CURX · Form: 8-K · Filed: Aug 27, 2025 · CIK: 2025942
| Field | Detail |
|---|---|
| Company | Curanex Pharmaceuticals Inc (CURX) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $4.00, $15,000,000, $12,114,369 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-event
TL;DR
Curanex Pharma filed an 8-K, check for updates.
AI Summary
Curanex Pharmaceuticals Inc. filed an 8-K on August 27, 2025, reporting under "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or event details beyond its classification.
Why It Matters
This 8-K filing indicates a corporate event or financial update from Curanex Pharmaceuticals Inc., requiring investor attention.
Risk Assessment
Risk Level: low — The filing is a standard procedural document without immediate disclosed financial impact or significant operational changes.
Key Players & Entities
- Curanex Pharmaceuticals Inc (company) — Registrant
- August 27, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 2 Jericho Plaza, Suite 101B Jericho, NY 11753 (address) — Principal executive offices
- 718-673-6078 (phone_number) — Registrant's telephone number
FAQ
What specific event triggered this 8-K filing?
The filing does not specify the exact event, only that it falls under 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 27, 2025.
What is Curanex Pharmaceuticals Inc.'s state of incorporation?
Curanex Pharmaceuticals Inc. is incorporated in Nevada.
What is the principal executive office address for Curanex Pharmaceuticals Inc.?
The principal executive office is located at 2 Jericho Plaza, Suite 101B Jericho, NY 11753.
What is the filing date for this 8-K report?
The filing was made on August 27, 2025.
Filing Stats: 600 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-08-27 17:05:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CURX The Nasdaq Capital M
- $4.00 — Stock"), at a public offering price of $4.00 per share. The Shares were offered by t
- $15,000,000 — r share, for gross Offering proceeds of $15,000,000. The net proceeds to the Company from
- $12,114,369 — d Offering expenses, were approximately $12,114,369. Following the closing of the Offering,
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001493152-25-012404.txt ( ) — 239KB
- curx-20250827.xsd (EX-101.SCH) — 3KB
- curx-20250827_lab.xml (EX-101.LAB) — 33KB
- curx-20250827_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Curanex Pharmaceuticals Inc Date: August 27, 2025 By: /s/ Jun Liu Name: Jun Liu Title: Chief Executive Officer